Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Ciclosporin/Emapalumab/Methylprednisolone

Lack of efficacy and off label use

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Bracaglia C, et al. Emapalumab treatment followed by hematopoietic stem cell transplantation in systemic juvenile idiopathic arthritis complicated by recurrent macrophage activation syndrome. Pediatric Rheumatology 21 (Suppl.): Oct 2023. Available from: URL: https://dx.doi.org/10.1186/s12969-023-00879-8 [abstract] Bracaglia C, et al. Emapalumab treatment followed by hematopoietic stem cell transplantation in systemic juvenile idiopathic arthritis complicated by recurrent macrophage activation syndrome. Pediatric Rheumatology 21 (Suppl.): Oct 2023. Available from: URL: https://​dx.​doi.​org/​10.​1186/​s12969-023-00879-8 [abstract]
Metadaten
Titel
Ciclosporin/Emapalumab/Methylprednisolone
Lack of efficacy and off label use
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57324-x

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Prednisolone

Case report

Nafcillin

Case report

Metformin